Core Laboratories (CLB) Asset Writedowns and Impairment (2023 - 2026)

Core Laboratories has reported Asset Writedowns and Impairment for 4 years, with the latest figure at $168000.0 in Q1 2026.

• For the quarter ending Q1 2026, Asset Writedowns and Impairment rose 394.12% year-over-year to $168000.0; the trailing twelve-month figure through Mar 2026 stood at $2.4 million (up 3.41% YoY), and the FY2025 full-year result was $2.3 million, down 22.88% from the prior year.
• Asset Writedowns and Impairment for Q1 2026 stood at $168000.0, down from $2.2 million in the prior quarter.
• The five-year high for Asset Writedowns and Impairment was $2.2 million in Q4 2025, with the low at -$151000.0 in Q2 2024.
• Historically, Asset Writedowns and Impairment has averaged $708200.0 across 4 years, with a median of $593500.0 in 2023.
• Annual changes were most pronounced in 2025 — Asset Writedowns and Impairment sank 94.77% — and 2026, when it jumped 394.12%.
• Core Laboratories' Asset Writedowns and Impairment stood at $576000.0 in 2023, then surged by 216.49% to $1.8 million in 2024, then climbed by 22.22% to $2.2 million in 2025, then tumbled by 92.46% to $168000.0 in 2026.
• The last three Asset Writedowns and Impairment figures came in at $168000.0 (Q1 2026), $2.2 million (Q4 2025), and $34000.0 (Q1 2025), per Business Quant data.